Loading…
Kyverna Therapeutics, Inc. is projected to rise to $9.17 by 2027, a +8% move from its current price of $8.49. KYTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $8.13 | $8.48 | $8.85 | 0.00% |
| Jul 14 | $7.99 | $8.48 | $9.01 | -0.01% |
| Jul 15 | $7.89 | $8.48 | $9.13 | -0.01% |
| Jul 16 | $7.80 | $8.48 | $9.23 | -0.02% |
| Jul 17 | $7.72 | $8.48 | $9.32 | -0.02% |
| Jul 18 | $7.65 | $8.48 | $9.41 | -0.03% |
| Jul 19 | $7.59 | $8.48 | $9.48 | -0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.59 | $8.48 | $9.48 | -0.03% |
| Week 2 | $7.24 | $8.48 | $9.93 | -0.07% |
| Week 3 | $6.99 | $8.48 | $10.28 | -0.10% |
| Week 4 | $6.78 | $8.47 | $10.59 | -0.14% |
| Week 5 | $6.60 | $8.47 | $10.87 | -0.17% |
| Week 6 | $6.44 | $8.47 | $11.13 | -0.21% |
| Week 7 | $6.30 | $8.46 | $11.37 | -0.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kyverna Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product.
The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Kyverna Therapeutics, Inc., ticker KYTX, is a healthcare company currently trading at $8.49 per share with a market cap of $515.85M and a rank of 3011. Its market position reflects a small-cap biotechnology focus within the late-stage biopharmaceutical space.
The asset’s price outlook shows a progression from neutral to bullish in the later years, with 2026–2029 forecasts drifting higher and 2030 onward entering a stronger uptrend. The forecasted average prices reach $11.60 by 2030, $31.91 by 2040, and $67.17 by 2050, with corresponding ROI figures of 36.7, 276.1, and 691.7 respectively, and sentiment turning bullish in 2030 and beyond.
A major floor 27.1% below — a decisive break under it would weaken the trend.
The nearest floor, 12.0% below — buyers have tended to step in here.
The nearest ceiling, 16.8% above — a clean break opens room to run.
A major ceiling 32.6% above — clearing it would confirm fresh momentum.
Key KYTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KYTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.41 | Sell | $9.18 | Sell |
| MA 10 | $9.05 | Sell | $9.05 | Sell |
| MA 20 | $8.61 | Sell | $8.81 | Sell |
| MA 50 | $8.73 | Sell | $8.70 | Sell |
| MA 100 | $8.70 | Sell | $8.55 | Sell |
| MA 200 | $8.18 | Buy | $7.94 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.09 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -16.75 | Neutral |
| Williams %R (14) | -83.33 | Info |
| MACD (12,26,9) | 0.11 | Buy |
| ROC (12) | 0.65 | Buy |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 16.67 | Buy |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 0.98 | Buy |
| Ultimate (7,14,28) | 47.53 | Neutral |
| Momentum (10) | 0.28 | Buy |
| Aroon Osc (25) | 84.00 | Buy |
| Hull MA (9) | 9.71 | Sell |
| ADX (14) | 15.23 | Neutral |
| ATR (14) | 0.34 | Info |
The 30-day technical picture for KYTX is bullish overall. RSI(14) sits at 50, with the 50-day moving average at $8.73 and the 200-day moving average at $8.18, signaling steady near-term momentum.
Key support is at $7.47 and resistance at $9.91. The 30-day price range spans from $6.43 to $11.21, indicating a relatively wide swing for a small-cap biotech stock. Annualized volatility is high at 80%, underscoring notable near-term risk.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.26 | $8.49 | $10.97 | 0% | Neutral | |
| $6.93 | $9.17 | $13.03 | +8% | Neutral | |
| $6.76 | $9.37 | $14.04 | +10% | Neutral | |
| $7.01 | $10.09 | $15.74 | +19% | Neutral | |
| $7.78 | $11.60 | $18.73 | +37% | Bullish | |
| $10.11 | $15.56 | $25.87 | +83% | Bullish | |
| $11.54 | $18.31 | $31.25 | +116% | Bullish | |
| $10.22 | $16.68 | $29.16 | +97% | Bullish | |
| $10.40 | $17.44 | $31.14 | +106% | Bullish | |
| $11.13 | $19.18 | $34.94 | +126% | Bullish | |
| $16.34 | $31.91 | $63.12 | +276% | Bullish | |
| $30.23 | $67.17 | $149.37 | +692% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $7.26 | $8.49 | $10.58 | +0.00% |
| August 2026 | $7.39 | $8.86 | $10.99 | +4.36% |
| September 2026 | $6.97 | $8.45 | $10.66 | -4.62% |
| October 2026 | $6.76 | $8.27 | $10.58 | -2.11% |
| November 2026 | $6.89 | $8.49 | $10.99 | +2.72% |
| December 2026 | $6.75 | $8.39 | $10.97 | -1.24% |
Click any year to see its month-by-month KYTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect KYTX to range from $7.26 to $10.97 through 2026. The $8.49 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The KYTX price prediction for 2027 points to an average of $9.17 (low $6.93, high $13.03) — a potential gain of +8% on today's $8.49. Price action looks broadly range-bound.
In 2028, KYTX is projected to trade between $6.76 and $14.04, averaging $9.37 — a potential gain of +10% from today's $8.49. That is up +2% on the projected 2027 average. A consolidation phase looks the most probable path here.
Kyverna Therapeutics, Inc.'s 2029 outlook centres on $10.09, within a $7.01 to $15.74 range. That is up +8% on the projected 2028 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2030, KYTX could reach as high as $18.73, with a base case around $11.60 and support toward $7.78 — roughly +37% from $8.49. Buyers look set to stay in control over this stretch.
Expect KYTX to range from $10.11 to $25.87 through 2031. The $15.56 average target implies a +83% move from current prices. That is up +34% on the projected 2030 average. Momentum favours further upside here.
The KYTX price prediction for 2032 points to an average of $18.31 (low $11.54, high $31.25) — a potential gain of +116% on today's $8.49. Buyers look set to stay in control over this stretch.
In 2033, KYTX is projected to trade between $10.22 and $29.16, averaging $16.68 — a potential gain of +97% from today's $8.49. That is -9% versus the projected 2032 average. Momentum favours further upside here.
Kyverna Therapeutics, Inc.'s 2034 outlook centres on $17.44, within a $10.40 to $31.14 range. That is up +5% on the projected 2033 average. That marks a +106% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, KYTX could reach as high as $34.94, with a base case around $19.18 and support toward $11.13 — roughly +126% from $8.49. Momentum favours further upside here.
Expect KYTX to range from $16.34 to $63.12 through 2040. The $31.91 average target implies a +276% move from current prices. That is up +66% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The KYTX price prediction for 2050 points to an average of $67.17 (low $30.23, high $149.37) — a potential gain of +692% on today's $8.49. Momentum favours further upside here.
Investing $1,000 in KYTX today (≈ 117.855038 KYTX) could be worth
$7,916.67
+$6,916.67 (+692%) by 2050 · US Dollar
Based on the average projected KYTX price of $67.17 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KYTXwould be worth at today's price.
$1,000 invested in KYTX on Jul 10, 2025 (≈ 280.11205 KYTX) would be worth
$2,376.75
+$1,376.75 (+137.7%) today · 2.38× · US Dollar
Based on a KYTX entry price of $3.57 vs. today's $8.49.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.89 | $954.44 | -4.6% |
| 1 month ago | $7.66 | $1,107.7 | +10.8% |
| 3 months ago | $8.95 | $948.04 | -5.2% |
| 6 months ago | $8.23 | $1,030.98 | +3.1% |
| 1 year ago | $3.57 | $2,376.75 | +137.7% |
| All time (2.4y) ago | $30.1 | $281.89 | -71.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KYTX forecast.
Our base-case forecast reaches $17.00 around 2032.
Implied market cap at $17.00: $1.03B
The multi-year forecast points to meaningful upside for KYTX beyond 2030. In 2030 the average price is projected at $11.60 with a max of $18.73 and a min of $7.78, and ROI of 36.7, with a bullish sentiment.
By 2040, the average rises to $31.91 (min $16.34, max $63.12) and ROI increases to 276.1, with continued bullish sentiment.
In 2050 the forecast shows an average of $67.17 (min $30.23, max $149.37) and ROI of 691.7, with bullish sentiment prevailing. These figures illustrate substantial potential upside over the long term but remain subject to uncertainty and are not guarantees. Shorter-term iterations from 2026–2029 show gradual improvement, with 2026-Avg $8.49, 2027-Avg $9.17, 2028-Avg $9.37, and 2029-Avg $10.09, among other figures.
Tap a question to reveal the answer.
In 2030 the average price is projected at $11.60 with a min of $7.78 and a max of $18.73, and ROI of 36.7, with a bullish sentiment.
Forecasts show sentiment turning bullish from 2030 onward, with a 2030 average of $11.60 and higher in later years (e.g., 2040 average $31.91; 2050 average $67.17), but earlier years are Neutral and outcomes are not guaranteed.
The 2030 max in the forecast is $18.73, which is below $20.
The current price is $8.49 and the market cap is $515.85M.
RSI(14) is 50, SMA(50) is $8.73, SMA(200) is $8.18, with support at $7.47 and resistance at $9.91; the 30-day range is $6.43–$11.21.
Kyverna Therapeutics, Inc. Community Discussion
0Share your Kyverna Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.